“…[82][83][84] This observation could be explained by the fact that a very small amount of active BM is expected to be transferred with this type of CTA. 79,80,85 Furthermore, since the first successful transplantation of BM in humans in 1968, 86 much progress has been made in clinical use as well as in experimental models to treat non-life-threatening conditions through hematopoietic reconstitution. The extension of lower-risk protocols, such as the "non-total body irradiation" approach, to establish the state of mixed chimerism across MHC barriers seems to be an important point to reduce the toxicity occurring from the conditioning of the host.…”